Intelligence desk

Products

Signal Tracker Data Platform Data Enrichment API

Solutions

Deal Origination Executive Search For Sales Teams Corporate Development For Founders For Agencies For Investors Signal-Based Outbound Competitive Intelligence Funding Signals Competitor Monitoring

Explore

Companies Live Signals Markets Trends

Resources

Signal Checker Blog Integrations FAQ Contact Pricing
Login Start Free
ExonanoRNA logo — We specialize in the design and production of RNA nanopartic...

ExonanoRNA

We specialize in the design and production of RNA nanoparticles

Founded 2017 United States Columbus, United States 6 employees Biotechnology

General Information

Company Name ExonanoRNA
Founded Year 2017
Location United States Columbus, United States +1
Employees 6
Industries Biotechnology
Social

Get notified when ExonanoRNA moves

Funding, new markets, leadership changes, hiring surges — one e-mail, only when something happens.

Free · no account needed

About ExonanoRNA

ExonanoRNA is a biotechnology startup established in 2017, specializing in the design and production of RNA nanoparticles. The company aims to fill a market gap by commercially producing high-quality RNA nanoparticles for research and pre-clinical development. Their expertise lies in RNA nanotechnology which allows the integration of multiple functional RNA modules into one nanoparticle. The core activities of ExonanoRNA revolve around researching and developing innovative products in the RNA nanotechnology-based platforms for next-generation targeted drug delivery and disease diagnosis. The team, consisting of experienced scientists, efficiently coordinates a multidisciplinary effort to transition bio-nanotechnology, especially RNA nanotechnology, from the bench to the clinic. ExonanoRNA's slogan "We specialize in the design and production of RNA nanoparticles" encapsulates their specialization and expertise, positioning them as leaders in the field. Though no specific information about their headquarters location or previous investments is available, the potential for growth and impact in the biotechnology industry makes ExonanoRNA an intriguing prospect for venture capitalists looking to invest in innovative biotech startups.

Taxonomy: RNA nanoparticles, Nanotechnology-based drug delivery, Cancer therapeutics, Bio-nanotechnology, Biomedical research, Oligonucleotide synthesis, Nucleic acid therapeutics, Medical technology, Molecular biology, Biomedical engineering

No funding data available for ExonanoRNA yet.

Get notified when ExonanoRNA raises funding

ExonanoRNA Alternatives & Competitors

ExonanoRNA vs
NorthShore Bio
NorthShore Bio

NorthShore Bio is privately held company focused on unlocking molecular information. It has develope...

Series A
1 employees
Biotechnology
ExonanoRNA vs
Allegro Biotech
Allegro Biotech Belgium

Regenerative Biomedical Technology

Seed
9 employees
Biotechnology, Life Sciences
ExonanoRNA vs
Nanovis
Nanovis United States

Best in class nanotechnology surface company.

Series Unknown
23 employees
Biotechnology, Health Care

FAQ About ExonanoRNA

We specialize in the design and production of RNA nanoparticles
ExonanoRNA was founded in 2017.
ExonanoRNA is headquartered in Columbus, United States.
ExonanoRNA operates in the following industries: Biotechnology.
ExonanoRNA has approximately 6 employees.
Top alternatives and competitors to ExonanoRNA include NorthShore Bio, Allegro Biotech, Nanovis, Nanotechnology World, ReNAgade Therapeutics. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
ExonanoRNA and NorthShore Bio are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Don't just browse. Track.

Signal Tracker monitors ExonanoRNA and millions of companies for funding rounds, hiring surges, product changes, and 40+ signal types — so you never miss an opportunity.

Start Tracking — Free

One analytics cookie (Google Analytics). Cookie Policy